SEC Form 4

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				or Section 30(n) of the	Investment C	ompany Act of 1940						
				2. Issuer Name and Ti Zentalis Pharma			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) C/O ZENTALIS	(First)	(Middle)		3. Date of Earliest Trar 11/13/2023	isaction (Mont	h/Day/Year)	X	Officer (give title below)		(specify		
1359 BROADWAY, SUITE 801			4. If Amendment, Date	of Original Fil	ed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)							X	Form filed by On	e Reporting Per	son		
NEW YORK	NY	10018						Form filed by Mo Person	re than One Re	porting		
(City)	(State)	(Zip)		Rule 10b5-1(c) Transa	ction Indication	*					
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
	Tab	le I - N	on-Deriva	tive Securities Ac	quired, Di	sposed of, or Benef	icially	Owned				
Date		2. Transactio Date (Month/Day/	Execution Date,	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			

		(wonth/Day/rear)	o))			Reported	(1) (1150.4)	(Instr. 4)	L	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	11/13/2023		Р		5,000	Α	\$10.2896	254,800	D		
											-

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

L															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D (Insti	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	Amount of			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				L

Explanation of Responses:

Remarks:

<u>By: /s/ Melissa B. Epperly,</u>

Attorney-in-Fact for Kimberly 11/13/2023 Blackwell

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.